Description
PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
Article: PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
€3.03
Related products
-
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
1 year access Online Belgian Journal of Hematology (BJH)
€71.94 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart
